SCHEMBL10286757

SCHEMBL10286757

C[C@@H](O)[C@H](NC(=O)c1ccc(-c2ccc(NC(=O)[C@@H]3CCCCN3)cc2)cc1)C(=O)NO

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN3A Q9NY46 3/20 0.44
SCN9A Q15858 2/20 0.44
DHODH Q02127 1/20 0.42
CTSC P53634 2/20 0.41
CTSK P43235 1/20 0.41
KCNH2 Q12809 1/20 0.41
HTT P42858 1/20 0.40
ULK1 O75385 1/20 0.40
AAK1 Q2M2I8 1/20 0.40
HDAC3 O15379 1/20 0.40
HDAC4 P56524 1/20 0.40
HDAC1 Q13547 1/20 0.40
HDAC7 Q8WUI4 1/20 0.40
HDAC2 Q92769 1/20 0.40
HDAC10 Q969S8 1/20 0.40
HDAC11 Q96DB2 1/20 0.40
HDAC8 Q9BY41 1/20 0.40
HDAC6 Q9UBN7 1/20 0.40
HDAC9 Q9UKV0 1/20 0.40
HDAC5 Q9UQL6 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13825557 1.00 SCN3A (0.44) SCN3ASCN9ADHODHCTSCCTSK
SCHEMBL1109424 0.97 SCN3A (0.47) SCN3ASCN9ADHODHCTSCHTT
SCHEMBL13825558 0.97 SCN3A (0.47) SCN3ASCN9ADHODHCTSCHTT
SCHEMBL1109269 0.92
SCHEMBL13818803 0.90 CTSK (0.38) CTSCCTSKKCNH2
SCHEMBL403973 0.90 CTSK (0.38) CTSCCTSKKCNH2
SCHEMBL403972 0.90 CTSK (0.38) CTSCCTSKKCNH2
SCHEMBL400769 0.89 PFKFB2 (0.41) SCN3ASCN9A
SCHEMBL13818804 0.87 PFKFB2 (0.40) SCN3ASCN9A
SCHEMBL439085 0.87 PFKFB2 (0.40) SCN3ASCN9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8101640-B2 Antibacterial agents NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2012-01-24 US disclosed
US-8084615-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2011-12-27 US disclosed
US-7989660-B2 BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2011-08-02 US disclosed
US-20110172174-A1 Antibacterial agents NOVARTIS VACCINES AND DIAGNOSTICS INC. 2011-07-14 US disclosed
US-20080269221-A1 ANTIBACTERIAL AGENTS NOVARTIS VACCINES AND DIAGNOSTICS, INC. 2008-10-30 US disclosed
US-7358359-B2 Antibacterial agents UNIVERSITY OF WASHINGTON (US) 2008-04-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110172174-A1 Antibacterial agents MRPL21, SI, PGLS SCN3A 3248/4885SCN9A 2172/4885DHODH 351/4885
US-20080269221-A1 ANTIBACTERIAL AGENTS MRPL21, SI, PGLS SCN3A 3248/4885SCN9A 2172/4885DHODH 351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.